NCT02272686View on ClinicalTrials.gov

Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

June 3, 2016

Primary Completion Date

December 22, 2017

Study Completion Date

December 22, 2017

Conditions

Lymphoma

Interventions

DRUG

Ibrutinib

560 mg by mouth daily.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Pharmacyclics LLC.

All Listed Sponsors

collaborator

Pharmacyclics LLC.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02272686 - Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma | Biotech Hunter | Biotech Hunter